Ticker Details
CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
IPO Date:	October 8, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$916.59M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.24 | 3.04%
Avg Daily Range (30 D):	$0.22 | 4.28%
Avg Daily Range (90 D):	$0.18 | 3.73%

Institutional Daily Volume
Avg Daily Volume:	1.08M
Avg Daily Volume (30 D):	8.44M
Avg Daily Volume (90 D):	4.62M

Trade Size
Avg Trade Size (Sh.):	198
Avg Trade Size (Sh.) (30 D):	179
Avg Trade Size (Sh.) (90 D):	167

Institutional Trades
Total Institutional Trades:	1,135
Avg Institutional Trade:	$1.53M
Avg Institutional Trade (30 D):	$2.25M
Avg Institutional Trade (90 D):	$2.12M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.69M
Avg Closing Trade (30 D):	$2.86M
Avg Closing Trade (90 D):	$2.3M
Avg Closing Volume:	237.27K

News

Mar 18, 2026 @ 2:46 AM CytomX Therapeutics Announces Pricing of $250 Mill... Source: Cytomx Therapeutics, Inc.

Feb 4, 2026 @ 1:00 PM CytomX Therapeutics to Present at Upcoming Februar... Source: Not Specified

Nov 13, 2025 @ 1:00 PM CytomX Therapeutics to Present at the Jefferies Lo... Source: Cytomx Therapeutics

Oct 30, 2025 @ 12:00 PM CytomX Therapeutics to Report Third Quarter 2025 F... Source: Cytomx Therapeutics

Sep 25, 2025 @ 9:06 PM 12 Health Care Stocks Moving In Thursday's After-M... Source: Benzinga Staff Writer

Financials
	TTM	Q4 2025	FY 2025
Basic EPS
Diluted EPS
Revenue	$76.2M	$.66M	$76.2M
Gross Profit
Net Income / Loss	$-17.37M	$-26.51M	$-17.37M
Operating Income / Loss	$-22.36M	$-27.93M	$-22.36M
Cost of Revenue
Net Cash Flow	$-24.89M	$-21.02M	$-24.89M
PE Ratio